Dr.Uday Khire
Pharma, BioTech
- Dr. Uday Khire is a Synthetic/ medicinal chemist with exceptional track record.
- His Post-doctoral work include total synthesis of complex polyene macrolide antibiotic, Roflamycoin (JACS 1997, 2058) and developed asymmetric allenyl/ propargylboration of aldehydes. Worked as a medicinal chemist in a large pharmaceutical company for over 10 years in various therapeutic areas, mainly oncology.
- He is a Co-inventor of NexaVar (Sorafenib) which is approved as a first line therapy for kidney and liver cancer in US and other major markets.
- He Founded Cheminpharma, chemistry/ medicinal chemistry driven Service Company in 2007. Over 6 years delivered outstanding services to various biotechnology/ pharmaceutical companies.
- He Discovered novel, macrocyclic, potent MEK kinase inhibitor CIP-137401 (WO201104755A2). In-licensed “Protein Degradation and Control Technology using Small Molecule Shield-1”. With in-house research improved water insoluble ligand Shield-1 to highly water soluble and orally available ligand Aqua-Shield-1 (US20100267950).